Skip to main content

Akero Therapeutics, Inc.

AKRODelisted Dec 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001744659

Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 267 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
267
Q3 2025, +12 vs. previous quarter
13F value
$4.34B
Reported value at the end of Q3 2025
Superinvestors holding
0
At the end of Q3 2025

From SEC filings, in USD.

Revenue, FY2024
–
No comparable prior period
Net income, FY2024
-$252.1M
No comparable prior period
Free cash flow, FY2024
–
No comparable prior period
Revenue, Q3 FY2025
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Nov 28, 2025.

Short interest
4.20M
Shares sold short
Change
−121.5K
−2.8% vs. previous
Days to cover
3.96
At average daily volume

Superinvestors holding AKRO, Q3 2025

Go to the superinvestors tab

No superinvestor reported holding AKRO at the end of Q3 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by Akero Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 14, 2025 (view filing)Oct 104 daysCheng AndrewPresident and CEOSSale−30.0K$53.98−$1.62M−5.4%526.1K after10b5-1
Oct 9, 2025 (view filing)Oct 72 daysRolph TimothyChief Scientific OfficerSSale−12.5K$46.08−$576.0K−7.0%166.6K after2 lots10b5-1
Oct 3, 2025 (view filing)Oct 12 daysYoung JonathanChief Operating OfficerSSale−12.5K$47.75−$596.9K−6.0%196.9K after2 lots10b5-1
Sep 12, 2025 (view filing)Sep 111 dayYoung JonathanChief Operating OfficerSSale−586$43.02−$25.2K−0.3%196.9K after
Sep 12, 2025 (view filing)Sep 111 dayYale CatrionaChief Development OfficerSSale−659$43.02−$28.4K−0.7%90.8K after
Sep 12, 2025 (view filing)Sep 111 dayWhite William RichardChief Financial OfficerSSale−659$43.02−$28.4K−1.1%57.8K after
Sep 12, 2025 (view filing)Sep 111 dayRolph TimothyChief Scientific OfficerSSale−553$43.02−$23.8K−0.3%166.6K after
Sep 12, 2025 (view filing)Sep 10-112 daysCheng AndrewPresident and CEOSSale−31.8K$43.23−$1.37M−6.3%473.9K after4 lots10b5-1
Sep 10, 2025 (view filing)Sep 82 daysRolph TimothyChief Scientific OfficerSSale−12.5K$44.17−$552.1K−7.0%167.1K after2 lots10b5-1
Sep 4, 2025 (view filing)Sep 22 daysYoung JonathanChief Operating OfficerSSale−12.5K$46.09−$576.1K−6.0%197.5K after3 lots10b5-1

Top 10 13F holders, Q3 2025

See all 267 holders

The largest institutional positions in Akero Therapeutics, Inc. at the end of Q3 2025; share changes are against Q2 2025.

Institutions holding AKRO in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Janus Henderson Group PLC6,280,305$298.2M0.14%−458,251−6.8%Reduced
General Atlantic LLC5,733,989$272.2M8.17%00.0%Unchanged
BlackRock, Inc.5,702,634$270.8M0.00%−76,778−1.3%Reduced
RTW Investments, LP5,477,561$260.1M3.20%00.0%Unchanged
Vanguard Group Inc4,526,920$214.9M0.00%−2,708−0.1%Reduced
Wellington Management Group LLP4,251,861$201.9M0.04%+841,915+24.7%Added
Deep Track Capital, LP4,000,978$190.0M5.30%+958,380+31.5%Added
Avoro Capital Advisors LLC3,955,555$187.8M2.43%+455,555+13.0%Added
Price T Rowe Associates Inc3,809,859$180.9M0.02%−699,466−15.5%Reduced
State Street Corp3,414,306$162.1M0.01%+668,742+24.4%Added

Holders of 5% or more of AKRO

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Akero Therapeutics, Inc..

Largest holders of AKRO from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
General Atlantic LLC13G/A8.40%6.80M shares–Mar 15, 20242 filingsMay 15, 2025SEC

1 member of Congress reported 1 trade in Akero Therapeutics, Inc. since 2020. Newest filings:

  1. Chris Jacobs

    House · NY · Dec 12, 2022

    Buy$1K-$15K